Intellia Therapeutics Inc Stock
We can see a decrease in the price for Intellia Therapeutics Inc. Compared to yesterday it has lost -€0.215 (-1.940%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 22 Buy predictions and 7 Sell predictions.
With a target price of 25 € there is potential for a 132.77% increase which would mean more than doubling the current price of 10.74 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.940% | 7.421% | -1.558% | -7.969% | 37.586% | -71.512% | -82.034% |
| Chromadex Corp | -0.480% | -4.186% | -21.524% | -22.264% | -25.091% | 146.633% | -35.118% |
| Cardio3 Biosciences S.A. | 42.950% | 73.541% | 225.547% | -12.720% | 230.370% | -62.584% | -93.020% |
| Polynovo Ltd | -5.360% | 0.000% | -15.200% | -52.679% | -22.059% | -62.937% | -66.242% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
News
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares